Galmed Pharmaceuticals将收购Colospan,打造聚焦胃肠疾病、瞄准60亿美元市场的平台

美股速递
Jun 08

Galmed Pharmaceuticals Ltd.(纳斯达克:GLMD)宣布,将收购Colospan公司,旨在整合双方优势,打造一个专注于胃肠疾病(GI)领域的综合平台。此举意在共同瞄准一个规模高达60亿美元的巨大市场。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10